Company Overview and News

to your dashboard

Headline News highlights: Natus Medical, GoPro, Enviva Partners and Bruker

2017-11-15 zacks
Chicago, IL – November 15, 2017 - Stocks in this week’s article include: Natus Medical Inc (BABY - Free Report) , GoPro Inc (GPRO - Free Report) , Enviva Partners LP (EVA - Free Report) and Bruker Corporation (BRKR - Free Report) . (64-0)

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bruker Corporation (BRKR)

2017-11-13 accesswire
NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bruker Corporation ("Bruker" or the "Company") (NASDAQ: BRKR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: (10-0)

Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

2017-11-10 zacks
On Nov 08, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The stock carries a Zacks Rank #3 (Hold). (13-0)

Bruker (BRKR) a Buy on Strong Quant Score

2017-11-09 investorplace
Bruker Corp (NASDAQ:BRKR) is classified as a component of the 33 company Life Sciences Tools & Services GICS industry group, which is part of the 785 company GICS Health Care sector. BRKR's market value is $5.3 billion which falls in the upper half of its industry group. The ranking for BRKR by Portfolio Grader places it 9 among the 33 companies in this industry group, placing it in the top half; in the top quartile of the sector with a ranking of 98 among the 785 companies in the sector, and number 641 in the nearly 5,000 company Portfolio Grader universe. (10-0)

Bruker (BRKR) in Focus: Stock Moves 6.5% Higher

2017-11-06 zacks
Bruker Corporation (BRKR - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $29.99 to $31.89 in the past one-month time frame. (10-0)

Bruker Corporation 2017 Q3 - Results - Earnings Call Slides

2017-11-06 seekingalpha
The following slide deck was published by Bruker Corporation in conjunction with their 2017 Q3 earnings call. (10-0)

Bruker (BRKR) Q3 2017 Results - Earnings Call Transcript

2017-11-03 seekingalpha
Good afternoon, and welcome to the Bruker's Third Quarter 2017 Earnings Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please also note today's event is being recorded. (10-0)

Bruker Corporation to Host Earnings Call

2017-11-02 accesswire

Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

2017-10-13 zacks
Bruker Corporation (BRKR - Free Report) scaled a new 52-week high of $30.93 on Oct 12, eventually closing a bit lower at $30.71. This Zacks Rank #3 (Hold) stock has a market cap of $4.88 billion. (93-0)

Microscopy Market Worth 7.39 Billion USD by 2022

2017-10-09 prnewswire
According to a new market research "Microscopy Market by Product (Microscopes, Accessories), Type (Optical Microscope, Electron Microscope, AFM, STM, NSOM), Application (Semiconductor, Nanotechnology, Electronics), End User (Industrial, Research Institute, Blood Bank) - Global Forecast to 2022", published by MarketsandMarkets™, the global market is expected to reach USD 7.39 Billion by 2022 from USD 5. (10-0)

Featured Company News - Bruker Introduces Additional Key Products for Diagnosis and Susceptibility Testing of Invasive Fungal Diseases

2017-10-09 accesswire
LONDON, UK / ACCESSWIRE / October 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bruker Corp. (NASDAQ: BRKR), following which we have published a free report that can be viewed by signing up at The Company announced on October 06, 2017, the introduction of the new CE-IVD marked Fungiplex® Candida fast diagnostic assay, a multiplex real-time PCR test for the rapid identification of the most common pathogens associated with invasive candidiasis at the Trends in Medical Mycology conference in Belgrade, Serbia. (25-0)

Bruker Corporation Introduces Additional Key Products For Diagnosis And Susceptibility Testing Of Invasive Fungal Diseases (IFD) Into European Clinical Microbiology Markets

2017-10-06 devicespace
BELGRADE, Serbia, Oct. 6, 2017 /PRNewswire/ -- At the Trends in Medical Mycology ( conference, Bruker today introduces the new, CE-IVD marked Fungiplex® Candida fast diagnostic assay, a multiplex real-time PCR test for the rapid identification of the most common pathogens associated with invasive candidiasis.  The new Fungiplex Candida assay does not require any culture steps, and typically gives results in just 2-3 hours directly from patient blood, plasma or serum samples. (10-0)

Bruker Introduces Additional Key Products for Diagnosis and Susceptibility Testing of Invasive Fungal Diseases (IFD) into European Clinical Microbiology Markets

2017-10-06 prnewswire
Fungiplex® Candida fast identification assay and MICRONAUT™-AM antifungal susceptibility testing (AFST) further expand Bruker´s product range in Invasive Fungal Disease (IFD) testing (10-0)

Microbial Identification Market to Garner US$ 1.4 Bn by 2022 - Future Market Insights

2017-10-05 prnewswire
FMI has recently published an exclusive forecast report on the global market for microbial identification. In the foreseeable future, improvements in techniques adopted by microbiologists for identifying pathogens and examining microbial cultures will factor developments in microbial identification systems. From healthcare to food & beverage, the vital use of microbial identification in applied research projects will continue to boost the growth of the global microbial identification market. (40-0)

Preclinical Imaging Market to Grow at CAGR Above 8% From 2014 to 2024: Million Insights

2017-10-05 prnewswire
The global preclinical imaging market size was worth USD 1.8 billion in 2015, which is anticipated to grow at a CAGR of more than 8.1% during the forecast period. Constant technological advancements and increasing expenditure on research and development are some of the leading factors for such huge market size with more and more pharmaceutical companies targeting this market. Similarly, rise in the number of contract research manufacturing and increasing presence of medical device companies that comply well with the pre-clinical studies in in-vivo experiments would further drive the market growth. (27-0)

CUSIP: 116794108